Analysts expect argenx to report Q3 2026 revenue of $1.63 billion and EPS of $7.44, with the stock trading around $869.72 against a consensus target of $1,153.00.
Investors are primarily focused on the commercial trajectory of Vyvgart Hytrulo, specifically its uptake in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market following its 2024 launch.
Recent success in the Phase 3 ALKIVIA trial for autoimmune myositis has bolstered the "pipeline-in-a-product" thesis, potentially expanding the company's addressable market significantly. Markets are also looking for progress on the subcutaneous pre-filled syringe transition, which now accounts for over 80% of total franchise prescriptions.